Discontinuation of adalimumab without functional and structural damage progression after attaining sustained remission in patients with rheumatoid arthritis: An observational study

Trial Profile

Discontinuation of adalimumab without functional and structural damage progression after attaining sustained remission in patients with rheumatoid arthritis: An observational study

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms HONOR
  • Most Recent Events

    • 08 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 03 Oct 2016 Retrospective sub-group analysis data presented at the American College of Rheumatology 2016 Annual Meeting, as per Myriad Genetics media release.
    • 01 Jul 2016 Results (correction to citation #3104218) published in the Annals of the Rheumatic Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top